Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.

CAS：150812-12-7
中文别名：2,4-二氯-7-对甲苯磺酰基-7H-吡咯并[2,3-D]嘧啶;2-氨基-4-(4-氟苄基氨基)-1-乙氧羰基氨基苯;
英文别名：D-23129, Ezogabine, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester;Retigabine;
分子式：C16H18FN3O2
分子量：303.331
精确质量：303.138
Psa：76.38
Logp：4.3156

UNII：12G01I6BBU

密度：1.307 g/cm3
沸点：430ºC at 760 mmHg
闪点：213.9ºC
折射率：1.655
蒸汽压：1.34E-07mmHg at 25°C

信号词：Danger
危险性防范说明：P273; P301 + P310 + P330; P391; P501
危险性描述：H301; H410
危险标志：GHS06, GHS09